Nuvation Bio Inc.
NUVB
$2.23
-$0.13-5.51%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 381.08% | 376.97% | 151.76% | 114.24% | -4.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 207.38% | 186.37% | 85.38% | 1,705.59% | -23.84% |
| Operating Income | -192.11% | -158.95% | -82.62% | -1,700.10% | 23.84% |
| Income Before Tax | -259.90% | -258.63% | -109.73% | -2,140.76% | 31.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -259.90% | -258.63% | -109.73% | -2,140.76% | 31.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -259.90% | -258.63% | -109.73% | -2,140.76% | 31.92% |
| EBIT | -192.11% | -158.95% | -82.62% | -1,700.10% | 23.84% |
| EBITDA | -191.42% | -158.58% | -82.39% | -1,703.03% | 23.90% |
| EPS Basic | -132.89% | -132.86% | -67.89% | -1,903.92% | 32.02% |
| Normalized Basic EPS | -132.94% | -132.15% | -67.74% | -1,912.10% | 31.72% |
| EPS Diluted | -128.57% | -132.86% | -67.89% | -1,903.92% | 29.51% |
| Normalized Diluted EPS | -132.94% | -132.15% | -67.74% | -1,912.10% | 31.72% |
| Average Basic Shares Outstanding | 54.58% | 53.86% | 24.95% | 11.83% | 0.14% |
| Average Diluted Shares Outstanding | 54.58% | 53.86% | 24.95% | 11.83% | 0.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |